Intravenous (IV) Compounding Automation Market Report 2026

Intravenous (IV) Compounding Automation Market Overview

• Intravenous (IV) Compounding Automation market size has reached to $2.19 billion in 2025 • Expected to grow to $3.79 billion in 2030 at a compound annual growth rate (CAGR) of 11.6% • Growth Driver: Growing Demand For Pharmaceutical Products Fueling The Growth Of The Market Due To The Need For Precise, Safe, And Scalable Medication Preparation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Intravenous (IV) Compounding Automation Market?

Intravenous (IV) compounding automation is the use of advanced robotic systems and software solutions to prepare intravenous medications with high accuracy and efficiency. It ensures precise dosage, reduces human error, and maintains sterility during the compounding process. It streamlines medication preparation workflows in healthcare settings while enhancing patient safety and operational productivity. The main product types of IV compounding automation are including robotic compounding systems, automated compounding devices, software solutions, and others. Robotic compounding systems refer to automated machines designed to prepare intravenous medications with high precision and accuracy, minimizing human error and contamination risk. These systems are supported by services such as installation, maintenance, training, consulting, system integration, validation, software updates, calibration, and remote monitoring. The applications across clinical areas including chemotherapy, parenteral nutrition, antibiotics, and others and the key end users such as hospitals, compounding pharmacies, oncology centers, and others.

What Is The Intravenous (IV) Compounding Automation Market Growth Forecast?

The intravenous (IV) compounding automation market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing investment in AI-enabled compounding solutions, growing implementation of automated IV workstations, rising integration of software with hospital information systems, expansion of remote monitoring and predictive maintenance, and increasing development of modular and customizable compounding systems. Major trends in the forecast period include innovation in AI and machine learning for compounding, advancement in robotic and automated devices, development of smart pump and monitoring technologies, innovation in sterile compounding isolators and safety cabinets, and advancement in compact and space-saving automation solutions.

Global Intravenous (IV) Compounding Automation Market Segmentation

1) By Product Type: Robotic Compounding Systems, Automated Compounding Devices, Software Solutions, Other Product Types 2) By Service: Installation, Maintenance, Training, Consulting, Support, System Integration, Validation, Software Updates, Calibration, Remote Monitoring 3) By Application: Chemotherapy, Parenteral Nutrition, Antibiotics, Other Applications 4) By End-User: Hospitals, Compounding Pharmacies, Oncology Centers, Other End-Users Subsegments: 1) By Robotic Compounding Systems: Robotic Arm Based Systems, Closed System Robotic Compounding Units, Hazardous Drug Handling Robots, Sterile Preparation Robotic Platforms 2) By Automated Compounding Devices: Volumetric Compounding Devices, Gravimetric Compounding Devices, Multi Chamber Compounding Units, Automated Parenteral Nutrition Compounding Devices 3) By Software Solutions: Compounding Workflow Management Software, Dose Verification Software, Barcode Based Medication Safety Software, Compounding Data Analytics And Reporting Software 4) By Other Product Types: Semi Automated Compounding Systems, Isolator Based Compounding Systems, Sterile Admixture Preparation Cabinets, Hybrid Compounding Assistance Devices

What Are The Drivers Of The Intravenous (IV) Compounding Automation Market?

The growing demand for pharmaceutical products is expected to propel the growth of the intravenous (IV) compounding automation market going forward. A pharmaceutical product is a substance or combination of substances formulated for diagnosing, treating, preventing, or alleviating diseases and medical conditions in humans or animals. IV compounding automation supports pharmaceutical products by enabling precise, safe, and efficient preparation of complex intravenous medications, ensuring accurate dosing, reducing contamination risks, and allowing healthcare providers to meet the growing demand for high-quality therapies. For instance, in November 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association, the total pharmaceutical production in Europe accounted for €390,000 million ($422,803 million) in 2023, up from €363,300 million ($393,857 million) in 2022. Therefore, the growing demand for pharmaceutical products is driving the growth of the intravenous (IV) compounding automation industry. The expanding use of personalized medicine and complex infusion protocols is expected to propel the growth of the intravenous (IV) compounding automation market going forward. Personalized medicine is the approach of tailoring medical treatments, including drug selection and dosing, to individual patient characteristics such as genetics, biomarkers, and disease profiles. The expansion of personalized medicine is driven by the increasing approval and clinical adoption of targeted therapies that require highly customized intravenous dosing and preparation. IV compounding automation supports this shift by enabling the accurate, reproducible, and safe preparation of complex, patient-specific infusion protocols while minimizing human error and contamination risks. For instance, in November 2025, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the US Food and Drug Administration approved 18 new personalized medicines in 2024, accounting for more than 25% of all new drug approvals, following 20 personalized medicine approvals in 2023, many of which require individualized IV preparation. Therefore, the expanding use of personalized medicine and complex infusion protocols is driving the growth of the intravenous (IV) compounding automation industry.

Key Players In The Global Intravenous (IV) Compounding Automation Market

Major companies operating in the intravenous (iv) compounding automation market are Becton Dickinson and Company, Baxter International Inc., Grifols S.A., ICU Medical Inc., Omnicell Inc., Fresenius Kabi AG, Equashield Medical Ltd., Health Robotics S.r.l., Loccioni Group, Loccioni Group, OPTIMA pharma GmbH, Medimix Systems AG, ARxIUM Inc., General Healthy Co. Ltd., PharmaScope Onco Automation B.V., Comecer SpA, Syntegon Technology GmbH, Parata Pharmacy Automation, B. Braun SE, Aesynt Incorporated, Shenzhen Broadcare Robots Co. Ltd.

Regional Insights

North America was the largest region in the intravenous (IV) compounding automation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Intravenous (IV) Compounding Automation Market?

The intravenous (IV) compounding automation market includes revenues earned by entities by providing services such as installation, maintenance, training, consulting, support, system integration, validation, software updates, calibration, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The intravenous (IV) compounding automation market consists of sales of robotic compounding systems, automated IV workstations, IV workflow software, barcode scanners, safety cabinets, sterile compounding isolators, automated filling machines, smart pumps, sensors, and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Intravenous (IV) Compounding Automation Market Report 2026?

The intravenous (iv) compounding automation market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous (iv) compounding automation industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.